These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 16436720)
1. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Benjamin DK; Driscoll T; Seibel NL; Gonzalez CE; Roden MM; Kilaru R; Clark K; Dowell JA; Schranz J; Walsh TJ Antimicrob Agents Chemother; 2006 Feb; 50(2):632-8. PubMed ID: 16436720 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Groll AH; Mickiene D; Petraitiene R; Petraitis V; Lyman CA; Bacher JS; Piscitelli SC; Walsh TJ Antimicrob Agents Chemother; 2001 Oct; 45(10):2845-55. PubMed ID: 11557479 [TBL] [Abstract][Full Text] [Related]
3. Anidulafungin: a new echinocandin with a novel profile. Vazquez JA Clin Ther; 2005 Jun; 27(6):657-73. PubMed ID: 16117974 [TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. Dowell JA; Knebel W; Ludden T; Stogniew M; Krause D; Henkel T J Clin Pharmacol; 2004 Jun; 44(6):590-8. PubMed ID: 15145966 [TBL] [Abstract][Full Text] [Related]
13. A clinical review of echinocandins in pediatric patients. VandenBussche HL; Van Loo DA Ann Pharmacother; 2010 Jan; 44(1):166-77. PubMed ID: 20009006 [TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Krause DS; Simjee AE; van Rensburg C; Viljoen J; Walsh TJ; Goldstein BP; Wible M; Henkel T Clin Infect Dis; 2004 Sep; 39(6):770-5. PubMed ID: 15472806 [TBL] [Abstract][Full Text] [Related]
15. Echinocandins: the newest class of antifungals. Sucher AJ; Chahine EB; Balcer HE Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014 [TBL] [Abstract][Full Text] [Related]
16. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. Dowell JA; Schranz J; Baruch A; Foster G J Clin Pharmacol; 2005 Dec; 45(12):1373-82. PubMed ID: 16291712 [TBL] [Abstract][Full Text] [Related]
17. Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Estes KE; Penzak SR; Calis KA; Walsh TJ Pharmacotherapy; 2009 Jan; 29(1):17-30. PubMed ID: 19113794 [TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Cohen-Wolkowiez M; Benjamin DK; Piper L; Cheifetz IM; Moran C; Liu P; Aram J; Kashuba AD; Capparelli E; Walsh TJ; Hope WW; Smith PB Clin Pharmacol Ther; 2011 May; 89(5):702-7. PubMed ID: 21412233 [TBL] [Abstract][Full Text] [Related]
19. Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections? Tapısız A Expert Rev Anti Infect Ther; 2011 Mar; 9(3):339-46. PubMed ID: 21417873 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]